Guardant Health, Inc. — News

Guardant Health (GH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

zacks.com - 2026-07-23 11:06:15

Amova Asset Management Americas Inc. trimmed its position in shares of Guardant Health, Inc. (NASDAQ: GH) by 24.5% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 483,557 shares of the company's stock after selling 156,738 shares during the period.

defenseworld.net - 2026-07-21 03:15:56

Artisan Mid Cap Fund portfolio generated strong absolute returns and outpaced the Russell Midcap® Growth Index. Within IT, several semiconductor holdings produced exceptional returns, with multiple positions rising more than 100% during the period. During the quarter, we initiated new positions in Entegris, Modine Manufacturing and C.H. Robinson Worldwide.

seekingalpha.com - 2026-07-15 13:56:00

ISCG offers lower fees and broader diversification, while RZG's portfolio strategy has outperformed over the past five years

fool.com - 2026-07-13 06:45:23

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will report financial results for the second quarter 2026 after market close on Thursday, July 30, 2026. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Live audio of the webcast will be available on the “Investors” section of the company website at: www.guardanthealth.com. The webcast will.

businesswire.com - 2026-07-09 16:05:00

Guardant Health stock jumped Thursday after key competitor, Freenome, unveiled study results for its colon cancer blood test.

investors.com - 2026-07-09 13:05:03

ISCB offers ultra-low costs and 1,500+ holdings for diversification, while BBSC concentrates on fewer names with higher recent returns.

fool.com - 2026-07-07 13:18:54

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced its Shield™ blood test for colorectal cancer screening (CRC) is now covered for eligible UnitedHealth Group (UHG) members1, making it the first major commercial insurer to provide coverage for adults 45 or older amid rising CRC rates for adults under 652 and mortality for younger adults as the leading cause of cancer death for those under 50.3 Shield is the first and onl.

businesswire.com - 2026-07-01 14:50:00

Explore how portfolio size and sector exposure differ between these two small-cap ETFs, each offering unique advantages for investors.

fool.com - 2026-06-30 08:15:01

TD Cowen analysts estimate that the total addressable market for longevity healthcare exceeds $250 billion.

barrons.com - 2026-06-18 14:14:00

Not intended for distribution to U.S. newswire services or for dissemination in the U.S. Red Deer, Alberta--(Newsfile Corp. - June 15, 2026) - Gamehost Inc. (TSX: GH) ("Gamehost") announced that the Court of King's Bench of Alberta has granted the final order authorizing Gamehost to proceed with its previously announced transaction with Pure Casino Entertainment Limited Partnership ("Pure") pursuant to which a subsidiary of Pure will acquire all of the outstanding common shares of Gamehost (the "Gamehost Shares") for $13.65 in cash per share (the "Transaction"). The Transaction was approved at a special meeting of the shareholders of Gamehost (the "Gamehost Shareholders") held on June 11, 2026.

newsfilecorp.com - 2026-06-15 09:00:00

Red Deer, Alberta--(Newsfile Corp. - June 12, 2026) - Gamehost Inc. (TSX: GH) ("Gamehost") announced that its shareholders (the "Gamehost Shareholders") have approved its previously announced transaction with Pure Casino Entertainment Limited Partnership ("Pure") pursuant to which a subsidiary of Pure will acquire all of the outstanding common shares of Gamehost (the "Gamehost Shares") for $13.65 in cash per share (the "Transaction"). The Transaction was approved at a special meeting of the Gamehost Shareholders held on June 11, 2026 (the "Meeting").

newsfilecorp.com - 2026-06-12 13:25:00

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that the U.S. Food and Drug Administration (FDA) has approved Guardant360® CDx as a companion diagnostic (CDx) for Boehringer Ingelheim's HERNEXEOS® (zongertinib tablets), the first targeted therapy for adults with HER2 (ERBB2)-mutant advanced non-small cell lung cancer (NSCLC) as an initial treatment option. The approval enables Guardant360 CDx, a liquid biopsy test tha.

businesswire.com - 2026-06-11 08:05:00

This biotech has a one-of-a-kind colon cancer blood test. Shares broke out of a base on recent news.

investors.com - 2026-06-04 12:10:02

Pre-Market Stock Futures: Futures are trading lower on Tuesday, but the technology tsunami continued on Monday, as all major indices dipped into the red early on news that Iran was halting the peace negotiations and would block the Strait of Hormuz. But that sell-off lasted until about noon, before a big reversal, which, by that... Here Are Tuesday's Top Wall Street Analyst Research Calls: CoreWeave, Danaher, Hewlett Packard Enterprise, Intuit, Knight-Swift, Meta Platforms, Starwood Property Trust, Tripadvisor, and More

247wallst.com - 2026-06-02 08:11:52

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company and its research collaborators will present 38 abstracts,

gurufocus.com - 2026-05-28 09:00:00

PALO ALTO, Calif.--(BUSINESS WIRE)---- $GH--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company and its research collaborators will present 38 abstracts, as well as one oral presentation in partnership with Pfizer, showcasing advances in methylation-based tumor classification and liquid biopsy technology at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois taking place May 29 – June 2, 2026. Key data that will be prese.

businesswire.com - 2026-05-28 08:05:00

Guardant Health stock spiked Wednesday after the American Cancer Society recommended its blood test as a screening tool for colon cancer.

investors.com - 2026-05-27 09:11:26

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced that its FDA-approved Shield™ blood test is now included in updated Ameri

gurufocus.com - 2026-05-27 08:00:00

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced that its FDA-approved Shield™ blood test is now included in updated American Cancer Society (ACS) Colorectal Cancer (CRC) Screening Guidelines published today. The major screening guideline update recommends Shield as a choice for patients who decline or have not completed stool-based or visual examination screening tests. In an effort to address persistent screening gaps and.

businesswire.com - 2026-05-27 07:47:00

The U.S. Food and Drug Administration (FDA) on Wednesday approved Guardant Health Inc.'s (NASDAQ:GH) Guardant360 Liquid CDx test, expanding the company's blood-based comprehensive genomic profiling capabilities for patients with advanced cancer.

benzinga.com - 2026-05-20 12:07:40

The Food and Drug Administration approved Guardant Health's newest blood cancer test Wednesday, and the stock leaped to a three-month high.

investors.com - 2026-05-20 10:57:38

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that the U.S. Food and Drug Administration (FDA) has approved Guardan

gurufocus.com - 2026-05-20 09:00:00

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that the U.S. Food and Drug Administration (FDA) has approved Guardant360® Liquid CDx, advancing blood-based comprehensive genomic testing by integrating genomic and epigenomic insights and helping clinicians make better-informed treatment selection decisions for patients with advanced cancer. Guardant360 Liquid CDx is the largest FDA-approved liquid biopsy panel, assess.

businesswire.com - 2026-05-20 08:05:00

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that on April 21, 2026, the Compensation Committee of Guardant's Board of Directors approved the granting of restricted stock units (“RSUs”) representing 143,898 shares of its common stock to 267 new non-executive employees with a grant date of May 11, 2026 under the Guardant Health, Inc. 2023 Employment Inducement Incentive Award Plan (the “Inducement Plan”). The RSUs w.

businesswire.com - 2026-05-18 16:51:00

Guardant Health, Inc. delivered strong results in the first quarter, with accelerating revenue growth supported by the MRD and screening businesses. GH's Quest Diagnostics partnership, product upgrades, and expanded reimbursement are set to sustain strong fundamentals and revenue diversification. While Guardant's losses are still sizeable, the company is on a clear path to profitability, driven by the scaling on the MRD and screening businesses.

seekingalpha.com - 2026-05-15 14:36:24

Guardant Health, Inc. (GH) Presents at Bank of America Global Healthcare Conference 2026 Transcript

seekingalpha.com - 2026-05-12 16:00:46

Guardant Health, Inc. (GH) Q1 2026 Earnings Call Transcript

seekingalpha.com - 2026-05-08 05:21:18

While the top- and bottom-line numbers for Guardant Health (GH) give a sense of how the business performed in the quarter ended March 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

zacks.com - 2026-05-07 19:30:19

Guardant Health (GH) came out with a quarterly loss of $0.45 per share versus the Zacks Consensus Estimate of a loss of $0.47. This compares to a loss of $0.49 per share a year ago.

zacks.com - 2026-05-07 18:55:15

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today reported financial results for the quarter ended March 31, 2026. First Quarter 2026 Financial Highlights For the three-month period ended March 31, 2026, as compared to the same period of 2025: Reported total revenue of $301.7 million, an increase of 48%, driven by: Oncology revenue of $205.0 million, an increase of 36%, and approximately 86,000 oncology tests, an increase of 47%.

businesswire.com - 2026-05-07 16:05:00

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that the U.S. Food and Drug Administration (FDA) has approved the Guardant360® CDx liquid biopsy test as a companion diagnostic for VEPPANU (vepdegestrant). VEPPANU, jointly developed by Arvinas, Inc. and Pfizer Inc., is approved for the treatment of adults with estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-), estrogen receptor.

businesswire.com - 2026-05-04 08:05:00

First Financial Bancorp maintains a return on tangible common equity in the high teens, and we were able to buy the stock at an attractive valuation. We purchased shares of Guardant Health, as recent due diligence highlighted a stable competitive environment and underscored a number of positive catalysts for the company over the next several years. We exited our position in Dynatrace, Inc. to redeploy capital to other higher conviction names following the broad software de-rating.

seekingalpha.com - 2026-05-01 10:56:00

Guardant Health (GH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

zacks.com - 2026-04-30 11:01:11

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced a multi-year strategic collaboration with Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, to support the development and potential commercialization of Nuvalent's oncology pipeline using the tissue and liquid offerings of the Guardant Infinity™ platf.

businesswire.com - 2026-04-30 08:05:00

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will be participating in the following investor conferences. BofA Securities 2026 Healthcare Conference in Las Vegas, NV Fireside chat on Tuesday, May 12th at 10:40 a.m. Pacific Time William Blair 46th Annual Growth Stock Conference in Chicago, IL Presentation on Tuesday, June 2nd at 9:20 a.m. Central Time Jefferies 2026 Global Healthcare Conference in New Yo.

businesswire.com - 2026-04-29 16:05:00

Guardant Health, Inc (NASDAQ:GH) shares are trading lower on Tuesday after the U.S. Food and Drug Administration (FDA) announced a review of AstraZeneca Plc's (NASDAQ:AZN) application for camizestrant for advanced breast cancer.

benzinga.com - 2026-04-28 14:30:05

B. Metzler seel. Sohn and Co. AG purchased a new stake in shares of Guardant Health, Inc. (NASDAQ: GH) in the undefined quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 8,918 shares of the company's stock, valued at approximately $911,000. Other hedge funds and

defenseworld.net - 2026-04-27 03:44:47